Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2021
Reporting Period: Second Quarter ended June 30, 2021
Context: The filing serves to announce the issuance of a press release containing the Company's results of operations and financial condition for the quarter ended June 30, 2021. The Company is an emerging growth company.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in this specific document. The filing solely references the announcement of results for the quarter ended June 30, 2021, without providing comparative data or analysis within the text provided.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release regarding Q2 2021 results but does not include the content of that commentary.
Forward-Looking Statements: The filing explicitly states that the information contained in Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933.
Risks and Contingencies: No specific risks or contingencies are listed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2021) for actual revenue, net loss, and cash position figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (SPRO) and exchange (Nasdaq Global Select Market) for the Common Stock.
- Check subsequent filings for detailed financial statements if the press release lacks granular data.